Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

Glioblastoma is the most common primary central nervous system malignancy and has a poor prognosis. Standard first-line treatment, which includes surgery followed by adjuvant radio-chemotherapy, produces only modest benefits to survival1,2. Here, to explore the feasibility, safety and immunobiologic...

Descripció completa

Dades bibliogràfiques
Autors principals: Schalper, K.A. (Kurt A.), Rodriguez-Ruiz, M.E. (María Esperanza), Diez-Valle, R. (Ricardo), López-Janeiro, Á. (Álvaro), Porciuncula, A. (Angelo), Idoate, M.A. (Miguel Ángel), Inoges, S. (Susana), Andrea, C.E. (Carlos Eduardo) de, Lopez-Diaz-de-Cerio, A. (Ascensión), Tejada-Solis, S. (Sonia), Berraondo, P. (Pedro), Villarroel-Espindola, F. (Franz), Choi, J. (Jungmin), Gurpide, A. (Alfonso), Giraldez, M. (Miriam), Goicoechea, I. (Iosune), Gallego-Perez-Larraya, J. (Jaime), Fernandez-Sanmamed, M. (Miguel), Perez-Gracia, J.L. (Jose Luis), Melero, I. (Ignacio)
Format: info:eu-repo/semantics/article
Idioma:eng
Publicat: Nature Publishing Group 2024
Matèries:
Materias Investigacion::Ciencias de la Salud::Oncología
Glioblastoma
Neoadjuvant nivolumab
Accés en línia:https://hdl.handle.net/10171/68722

Internet

https://hdl.handle.net/10171/68722

Ítems similars